As stated above, AML patients classified as monocytic FAB-M4/M5 AML are a heterogeneous group with regard to their genetic abnormalities and thereby also prognosis after intensive conventional chemotherapy, but NPM1-Ins patients then constitute a subset that probably share specific biological characteristics with relatively strong favorable prognostic impact. Here, NPM1 is linked to acute myeloid leukemia.